Meyka AI API is live for developers.Start building.
Advertisement
Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. (NBIX) Stock Overview

Explore Neurocrine Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

NBIX●NASDAQ
HealthcareBiotechnology
$168.52
$4.34(2.64%)
U.S. Market opens in 44h 36m
Advertisement

Neurocrine Biosciences, Inc. (NBIX)

Meyka AI Score

Z

Key Financials

Market Cap16.9B
P/E Ratio24.79
EPS (TTM)$6.92
ROE0.22%
Fundamental Analysis

AI Price Forecasts

1 Month$168.65
3 Months$159.36
1 Year Target$156.41

NBIX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Neurocrine Biosciences, Inc. (NBIX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 64.19, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $156.41.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 24.79 and a market capitalization of 16.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
2.64%
5-Day Change
4.56%
1-Month Change
8.21%
3-Month Change
27.26%
6-Month Change
16.01%
Year-to-Date (YTD) Change
18.82%
1-Year Change
33.00%
3-Year Change
75.38%
5-Year Change
71.40%
All-Time (Max) Change
1248.16%

Contact Information

https://www.neurocrine.com
858 617 7600
12780 El Camino Real, San Diego, CA, 92130

Company Facts

18,000 Employees
IPO DateMay 23, 1996
CountryUS
Actively Trading

Frequently Asked Questions